Follow
Daniel Bondeson
Daniel Bondeson
Broad Institute
Verified email at broadinstitute.org
Title
Cited by
Cited by
Year
Catalytic in vivo protein knockdown by small-molecule PROTACs
DP Bondeson, A Mares, IED Smith, E Ko, S Campos, AH Miah, ...
Nature chemical biology 11 (8), 611-617, 2015
10492015
Lessons in PROTAC design from selective degradation with a promiscuous warhead
DP Bondeson, BE Smith, GM Burslem, AD Buhimschi, J Hines, ...
Cell chemical biology 25 (1), 78-87. e5, 2018
6482018
The advantages of targeted protein degradation over inhibition: an RTK case study
GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ...
Cell chemical biology 25 (1), 67-77. e3, 2018
5112018
Targeted protein degradation by small molecules
DP Bondeson, CM Crews
Annual review of pharmacology and toxicology 57, 107-123, 2017
1632017
Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation
GM Burslem, AR Schultz, DP Bondeson, CA Eide, SL Savage Stevens, ...
Cancer research 79 (18), 4744-4753, 2019
1552019
In vivo Drosophilia genetic model for calcium oxalate nephrolithiasis
T Hirata, P Cabrero, DS Berkholz, DP Bondeson, EL Ritman, ...
American Journal of Physiology-Renal Physiology 303 (11), F1555-F1562, 2012
612012
Ion and solute transport by Prestin in Drosophila and Anopheles
T Hirata, A Czapar, L Brin, A Haritonova, DP Bondeson, P Linser, ...
Journal of insect physiology 58 (4), 563-569, 2012
312012
Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer
DP Bondeson, BR Paolella, A Asfaw, MV Rothberg, TA Skipper, ...
Nature cancer 3 (6), 681-695, 2022
262022
Scaffold hopping enables direct access to more potent PROTACs with in vivo activity
GM Burslem, DP Bondeson, CM Crews
Chemical communications 56 (50), 6890-6892, 2020
212020
Systematic profiling of conditional degron tag technologies for target validation studies
DP Bondeson, Z Mullin-Bernstein, S Oliver, TA Skipper, TC Atack, N Bick, ...
Nature communications 13 (1), 5495, 2022
132022
An In Vitro Pull-down Assay of the E3 Ligase: PROTAC: Substrate Ternary Complex to Identify Effective PROTACs
DP Bondeson, BE Smith, AD Buhimschi
Targeted Protein Degradation: Methods and Protocols, 135-150, 2021
22021
Therapeutic targeting of phosphate dysregulation in cancer via the xpr1: kidins220 protein complex
T Golub, D Bondeson, B Paolella, F Vazquez
US Patent App. 18/019,851, 2023
2023
Phosphate dysregulation as a novel therapeutic strategy in ovarian and uterine cancers
D Bondeson, B Paolella, A Asfaw, M Rothberg, T Skipper, G Mesa, ...
Cancer Research 82 (12_Supplement), 1028-1028, 2022
2022
In vivo Nanopool: Pooled sgRNA competition assays to evaluate in vivo cancer dependencies
T Skipper, D Bondeson, B Paolella, F Vazquez
2020
Targeted protein degradation as a tool to probe non-kinase roles in myeloid leukemias
G Burslem, A Schultz, D Bondeson, J Song, C Eide, S Savage, J Hines, ...
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 258, 2019
2019
Furthering the Scope, Understanding, and Application of Proteolysis Targeting Chimera
DP Bondeson
Yale University, 2018
2018
PROTACs: Potent protein knockdown by hijacking E3 ubiquitin ligases
D Bondeson, A Mares, I Smith, E Ko, S Campos, A Miah, K Mulholland, ...
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 250, 2015
2015
Small molecule‐induced catalytic ubiquitination of non‐natural substrates
D Bondeson, C Pancevac, L Kruidenier, P Carter, I Churcher, C Crews
The FASEB Journal 29, 573.43, 2015
2015
Real‐time visualization of calcium oxalate crystals in Drosophila‐a gut and renal model of kidney stones
DP Bondeson, T Hirata, P Cabrero, EL Ritman, JAT Dow, MF Romero
The FASEB Journal 26, 1152.25-1152.25, 2012
2012
2070 DEVELOPMENT OF DROSOPHILA KIDNEY STONE MODEL AND REAL-TIME VISUALIZATION OF CALCIUM OXALATE CRYSTAL FORMATION
T Hirata, P Cabrero, D Bondeson, D Berkholz, E Ritman, J Thompson, ...
The Journal of Urology 187 (4S), e835-e835, 2012
2012
The system can't perform the operation now. Try again later.
Articles 1–20